Attached files
| file | filename |
|---|---|
| EX-99.1 - OPIANT PHARMACEUTICALS, INC. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 25, 2011
Lightlake Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Nevada
|
333-139915
|
N/A
|
||
|
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
54 Baker Street, 6th Floor
London, England W1U 7BU
(Address of principal executive offices, including zip code)
44-207-034-1943
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events
On August 24, 2011, the Registrant released a press release announcing the start date of the Phase II Clinical Trials of its Binge Eating Disorder Treatment. More information can be found in the press release included as an exhibit to this Current Report on Form 8-K.
(d) Exhibits. The following exhibit is being filed herewith this Current Report on Form 8-K
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 25, 2011 By: /s/ Dr. Roger Crystal
Dr. Roger Crystal
Chief Executive Officer